Compare Stocks: ALNY, REGN, ARGX, and RVMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$205.52	$287.96	$197.81 ▼ $495.55	$27.50B	0.3	2.16 million shs	4.48 million shs
ARGX argenex	$853.82	$875.66	$631.47 ▼ $953.58	$53.41B	0.46	290,260 shs	294,615 shs
REGN Regeneron Pharmaceuticals	$762.63	$643.13	$541.00 ▼ $821.11	$80.63B	0.21	785,534 shs	1.16 million shs
RVMD Revolution Medicines	$187.53	$172.57	$34.00 ▼ $194.56	$39.87B	1.37	1.89 million shs	1.49 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-24.38%	-34.29%	-30.59%	-48.85%
ARGX argenex	0.00%	-7.01%	-9.14%	+8.98%	+26.72%
REGN Regeneron Pharmaceuticals	0.00%	+16.25%	+16.56%	+8.73%	+36.46%
RVMD Revolution Medicines	0.00%	-0.90%	-0.90%	+34.45%	+411.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$205.52	$287.96	$197.81 ▼ $495.55	$27.50B	0.3	2.16 million shs	4.48 million shs
ARGX argenex	$853.82	$875.66	$631.47 ▼ $953.58	$53.41B	0.46	290,260 shs	294,615 shs
REGN Regeneron Pharmaceuticals	$762.63	$643.13	$541.00 ▼ $821.11	$80.63B	0.21	785,534 shs	1.16 million shs
RVMD Revolution Medicines	$187.53	$172.57	$34.00 ▼ $194.56	$39.87B	1.37	1.89 million shs	1.49 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-24.38%	-34.29%	-30.59%	-48.85%
ARGX argenex	0.00%	-7.01%	-9.14%	+8.98%	+26.72%
REGN Regeneron Pharmaceuticals	0.00%	+16.25%	+16.56%	+8.73%	+36.46%
RVMD Revolution Medicines	0.00%	-0.90%	-0.90%	+34.45%	+411.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.83	Moderate Buy	$410.72	99.84% Upside
ARGX argenex	2.92	Moderate Buy	$1,056.89	23.78% Upside
REGN Regeneron Pharmaceuticals	2.70	Moderate Buy	$794.83	4.22% Upside
RVMD Revolution Medicines	2.95	Moderate Buy	$144.67	-22.85% Downside

Current Analyst Ratings Breakdown

Latest ALNY, REGN, ARGX, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	ALNY Alnylam Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
7/31/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	ALNY Alnylam Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$445.00 ➝ $350.00
7/31/2026	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$400.00 ➝ $375.00
7/31/2026	ALNY Alnylam Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$400.00 ➝ $300.00
7/31/2026	ALNY Alnylam Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$500.00 ➝ $350.00
7/31/2026	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$377.00 ➝ $316.00
7/31/2026	ALNY Alnylam Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$444.00 ➝ $318.00
7/31/2026	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$425.00
7/31/2026	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$696.00 ➝ $737.00
7/31/2026	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$730.00 ➝ $758.00

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	7.40	$2.80 per share	73.50	$5.97 per share	34.43
ARGX argenex	$4.25B	12.57	$21.33 per share	40.02	$118.34 per share	7.21
REGN Regeneron Pharmaceuticals	$14.34B	5.62	$41.97 per share	18.17	$295.66 per share	2.58
RVMD Revolution Medicines	$11.58M	3,442.91	N/A	N/A	$8.44 per share	22.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	38.20	20.55	N/A	15.26%	104.81%	14.71%	N/A
ARGX argenex	$1.29B	$26.04	32.79	23.87	1.08	32.19%	43.59%	36.66%	N/A
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	18.85	18.05	28.06	27.86%	13.47%	10.34%	N/A
RVMD Revolution Medicines	-$1.13B	-$7.07	N/A	N/A	N/A	N/A	-83.22%	-59.06%	8/5/2026 (Estimated)

Latest ALNY, REGN, ARGX, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	N/A	N/A	N/A	$1.77 million	N/A
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion
5/7/2026	Q1 2026	ARGX argenex	$5.74	$5.52	-$0.22	$5.52	$1.44 billion	$1.31 billion
5/6/2026	Q1 2026	RVMD Revolution Medicines	-$1.83	-$2.29	-$0.46	-$2.29	$2.43 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARGX argenex	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.49%	N/A	9.29%	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Latest ALNY, REGN, ARGX, and RVMD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.51%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.94	3.13	3.06
ARGX argenex	N/A	5.12	4.89
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
RVMD Revolution Medicines	0.19	6.80	6.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
ARGX argenex	60.32%
REGN Regeneron Pharmaceuticals	83.31%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
ARGX argenex	2.43%
REGN Regeneron Pharmaceuticals	6.97%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	105.72 million	98.35 million	Optionable
RVMD Revolution Medicines	250	212.60 million	196.44 million	Optionable

ALNY, REGN, ARGX, and RVMD Headlines

Recent News About These Companies

The Manufacturers Life Insurance Company Decreases Position in Revolution Medicines, Inc. $RVMD

14 minutes ago | marketbeat.com

Revolution Medicines, Inc. $RVMD Shares Sold by Defilade Capital Management L.P.

1 hour ago | marketbeat.com

First Trust Advisors LP Boosts Holdings in Revolution Medicines, Inc. $RVMD

1 hour ago | marketbeat.com

California State Teachers Retirement System Boosts Stock Position in Revolution Medicines, Inc. $RVMD

1 hour ago | marketbeat.com

Seven Fleet Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

August 2 at 6:31 AM | marketbeat.com

Perceptive Advisors LLC Purchases New Position in Revolution Medicines, Inc. $RVMD

August 2 at 6:07 AM | marketbeat.com

15,000 Shares in Revolution Medicines, Inc. $RVMD Bought by Avidity Partners Management LP

August 1 at 3:39 AM | marketbeat.com

Edgestream Partners L.P. Invests $6.74 Million in Revolution Medicines, Inc. $RVMD

July 31 at 4:02 AM | marketbeat.com

Dimensional Fund Advisors LP Sells 317,032 Shares of Revolution Medicines, Inc. $RVMD

July 31 at 3:30 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by Brokerages

July 31 at 2:15 AM | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 31 at 2:13 AM | marketbeat.com

Janus Henderson Group PLC Has $949.54 Million Holdings in Revolution Medicines, Inc. $RVMD

July 30, 2026 | marketbeat.com

Gabelli Funds LLC Purchases Shares of 15,750 Revolution Medicines, Inc. $RVMD

July 30, 2026 | marketbeat.com

Bank of Nova Scotia Decreases Position in Revolution Medicines, Inc. $RVMD

July 30, 2026 | marketbeat.com

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

July 29, 2026 | globenewswire.com

Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

Readystate Asset Management LP Takes Position in Revolution Medicines, Inc. $RVMD

July 29, 2026 | marketbeat.com

ADAR1 Capital Management LLC Lowers Stock Position in Revolution Medicines, Inc. $RVMD

July 29, 2026 | marketbeat.com

Revolution Medicines, Inc. $RVMD Shares Sold by Rock Springs Capital Management LP

July 28, 2026 | marketbeat.com

Weiss Asset Management LP Cuts Stake in Revolution Medicines, Inc. $RVMD

July 28, 2026 | marketbeat.com

Empyrean Capital Partners LP Takes $9.96 Million Position in Revolution Medicines, Inc. $RVMD

July 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALNY, REGN, ARGX, and RVMD Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$205.52 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$204.85 -0.67 (-0.33%)

As of 07/31/2026 07:59 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

argenex NASDAQ:ARGX

$853.82 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$846.80 -7.02 (-0.82%)

As of 07/31/2026 07:34 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Regeneron Pharmaceuticals NASDAQ:REGN

$762.63 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$761.50 -1.13 (-0.15%)

As of 07/31/2026 07:49 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Revolution Medicines NASDAQ:RVMD

$187.53 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$187.00 -0.53 (-0.28%)

As of 07/31/2026 07:59 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALNY, REGN, ARGX, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALNY, REGN, ARGX, and RVMD Earnings

Compare Dividends

Latest ALNY, REGN, ARGX, and RVMD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALNY, REGN, ARGX, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALNY, REGN, ARGX, and RVMD Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

argenex NASDAQ:ARGX

Regeneron Pharmaceuticals NASDAQ:REGN

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools